How does EVERSANA INTOUCH leverage AI to identify undiagnosed patients, as demonstrated in the AIVI case study?
EVERSANA INTOUCH utilizes its AIVI platform to analyze vast datasets and identify patient populations that are likely undiagnosed, as evidenced by a case study where AIVI helped identify 1.8 million additional undiagnosed patients. This capability allows for more targeted marketing and patient outreach strategies.
What are the "three pillars of success" for mastering content velocity that Angela Tenuta discusses for pharmaceutical companies?
Angela Tenuta, President of Agency at EVERSANA INTOUCH, outlines three pillars for mastering content velocity in pharmaceutical marketing: these are critical components that enable pharmaceutical companies to deliver brand content with unparalleled speed and effectiveness, though the specific pillars are not detailed on the main page.
Beyond applied AI, direct-to-patient models, and globalization, what other emerging trends does EVERSANA INTOUCH anticipate will impact pharma marketing by 2025?
While the primary trends highlighted for 2025 are applied AI, direct-to-patient models, and globalization, EVERSANA INTOUCH continuously monitors the industry. Their blog and insights sections provide ongoing analysis of additional powerful, digitally driven forces reshaping pharma marketing, offering expert recommendations to stay ahead.
How does EVERSANA INTOUCH ensure its commercial models are "futureproof" in the rapidly changing pharmaceutical market?
EVERSANA INTOUCH ensures its commercial models are futureproof by integrating best-in-breed technology, continuously enriching strategies with data and insights, and staying ahead of industry trends like applied AI and direct-to-patient engagement. This proactive approach allows them to adapt and evolve strategies to meet future market demands.
What kind of insights does EVERSANA INTOUCH typically gather from major industry events like ESMO to inform their client strategies?
From events like ESMO, EVERSANA INTOUCH gathers insights on the year’s biggest oncology breakthroughs and practice-changing advances. This includes understanding new anticancer therapies, research developments, and the perspectives of experts from pharma, research, advocacy organizations, and healthcare professionals, which directly informs their strategic recommendations for clients.